[{"id":"36d108df-7220-49ba-9e5c-6bcdaeaf319d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04092673","created_at":"2021-01-18T20:01:41.284Z","updated_at":"2024-07-02T16:35:02.263Z","phase":"Phase 1/2","brief_title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT04092673","lead_sponsor":"Effector Therapeutics","biomarkers":" KRAS • FGFR • CCND1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification","tags":["KRAS • FGFR • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Verzenio (abemaciclib) • Lumakras (sotorasib) • fulvestrant • zotatifin (eFT226)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"6accad76-76f1-4451-99f2-1a7ef5af528e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03344536","created_at":"2021-01-18T16:31:01.100Z","updated_at":"2024-07-02T16:35:59.970Z","phase":"Phase 1/2","brief_title":"A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT03344536","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR • FGFR • CCND1 • FGF3","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification","tags":["HER-2 • ER • PGR • FGFR • CCND1 • FGF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • zoligratinib (Debio 1347)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/10/2017","start_date":" 11/10/2017","primary_txt":" Primary completion: 08/12/2021","primary_completion_date":" 08/12/2021","study_txt":" Completion: 08/12/2021","study_completion_date":" 08/12/2021","last_update_posted":"2022-11-24"},{"id":"3e8f92c9-751f-48a5-a600-1fa3142b37ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450123","created_at":"2021-01-18T11:44:48.235Z","updated_at":"2024-07-02T16:36:08.898Z","phase":"","brief_title":"Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors","source_id_and_acronym":"NCT02450123","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR","pipe":" | ","alterations":" RET fusion • FGFR amplification • RET positive","tags":["RET • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR amplification • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 03/23/2016","start_date":" 03/23/2016","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2022-06-15"}]